Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga?) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study.

Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga?) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study. J Clin Immunol. 2017 Aug; 37(6):603-612.

View in: PubMed

subject areas

Adolescent
Adult
Bacterial Infections
Child
Child, Preschool
Female
Humans
Immunoglobulin G
Immunoglobulins
Immunologic Deficiency Syndromes
Immunologic Factors
Immunotherapy
Male
Middle Aged
Prospective Studies
Quality of Life
Treatment Outcome
Young Adult

authors with profiles

James Moy